New analysis finds GSK drug will overtake angiogenesis inhibitor market
WALTHAM, Mass. A new report by Decision Resources found that an angiogenesis inhibitor will garner sales of $640 million in less than 10 years, succeeding its current competition.
In their new report, entitled “Renal Cell Carcinoma”, Decision Resources finds that Votrient will overtake Sutent as the renal cell carcinoma market leader by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. In 2008, Sutent had accounted for 61% of sales in the angiogenesis inhibitor drug class.
Additionally the angiogenesis inhibitor drug class will continue to dominate this market over the next decade, capturing 87% of total sales in 2018, according to the report.
“Thought leaders we interviewed indicate that they are optimistic about several emerging therapies, most notably axitinib and Votrient,” said Decision Resources analyst Karen Pomeranz, M.Sc., Ph.D. “One expert called axitinib ‘the most exciting’ emerging agent in renal cell carcinoma in recent years and another thought leader said that Votrient’s clinical efficacy is comparable to that of Sutent and that Votrient has a more favorable side-effect profile than Sutent.”
Meanwhile, the report also finds that Novartis’s Afinitor and Pfizer’s axitinib will surpass Bayer Healthcare/Onyx’s Nexavar and Wyeth’s Torisel by 2018 in the second- and third-line treatment settings. In 2008, Nexavar was the leading therapy in the second-line setting and Torisel was the leading therapy in the third-line setting for the treatment of renal cell carcinoma.
FDA approves Par’s diabetes drug
WOODCLIFF LAKE, N.J. A generic drug maker has received final approval for a Type 2 diabetes treatment.
Par Pharmaceutical announced that the Food and Drug Administration approved its ANDA for nateglinide tablets. Nateglinide is a generic version of Novartis’ Starlix. Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
Par will begin shipping the 60-mg and 120-mg strengths of nateglinide to the trade immediately.
Annual U.S. sales of Starlix are approximately $124 million, according to IMS Health data.
Sweetbay Supermarket clinic to launch campaigns aimed at women
TAMPA, Fla. It has been several months since the opening the USF Health Neighborhood Care Center within Sweetbay Supermarket and, according to a local news report, the clinic is launching campaigns aimed at women.
The move is yet another indication that convenience care clinics are expanding their services to drive clinic utilization and further augment – not replace – the medical community.
The opening of the clinic was originally reported in the Aug. 10 issue of Drug Store News.
According to a recent Tampa Tribune article, the clinic, which opened in partnership with USF Health, is launching campaigns aimed at women ages 35 to 55 to sign up for a bone density screening. It is also urging area residents to come in for seasonal flu vaccinations.
Although the companies have yet to launch an advertising campaign, the paper states, the clinic receives two to three telephone calls a day from people seeking directions to the store.
The clinic currently offers treatment for acute ailments and offers such services as camp physicals and vaccines. Patients can them be referred to the network of more than 350 doctors in the USF Physicians Group for further treatment, if needed.
The clinic opening was a significant development for the 103-store grocery chain and a continuation of a relationship with USF Health that began last year when Sweetbay was selected to open two pharmacies inside USF facilities.
Sweetbay is owned by Belgium-based Delhaize Group, with also owns Food Lion and Hannaford.